Does HepPar-1 immunoexpression have a role in differential diagnosis of periampullary cancer?

Gulluoglu M., Karayigit E., Ozden I., Kapran Y., Dizdaroglu F.

PATHOLOGY, vol.40, no.1, pp.35-41, 2008 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 40 Issue: 1
  • Publication Date: 2008
  • Doi Number: 10.1080/00313020701716391
  • Journal Name: PATHOLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.35-41
  • Istanbul University Affiliated: Yes


Aims: Histological subtyping of periampullary carcinomas is considered as a criterion for prognosis and therapeutic implications of these tumours. We assessed the immunoexpression rates of HepPar-1, CDX2 and MUC2 antibodies in different subtypes of periampullary adenocarcinomas (PAC), intestinal and pancreatobiliary, in order to assess their impact on differential diagnosis of this group of cancers. The expression of antibodies was also measured in ductal adenocarcinoma of the pancreatic head (DAPH).